Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood ...

The global cancer monoclonal antibodies (mAbs) market , valued at $55.6 billion in 2021, is projected to reach $106.8 billion by 2031, growing at a CAGR of 7% from 2022 to 2031. This exponential ...

Regeneron Pharmaceuticals said on Wednesday the U.S. Food and Drug Administration has approved its drug for a type of blood ...

Engineered chip mimics bone marrow and immune system, offering a faster, tailored path for cancer immunotherapy.

The global HER2-positive breast cancer market is rapidly evolving due to rising prevalence and demand for targeted therapies. HER2-positive breast cancer, characterized by overexpression of HER2 ...

People with autoimmune skin diseases had significantly better cancer survival outcomes than others. Survival benefits were ...

Amgen’s investigational monoclonal antibody paired with chemotherapy significantly improved overall survival for patients in ...

CytoDyn announces encouraging clinical findings among patients with advanced metastatic colorectal cancer previously treated with leronlimab: Vancouver, Washington Friday, July 4, ...

Help is now there for those diagnosed with hard-to-treat blood cancers like leukemia and lymphoma, as new therapies are ...